RT Journal Article
SR Electronic
T1 Development of an automated chemiluminescence assay system for quantitative measurement of multiple anti-SARS-CoV-2 antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.04.20225805
DO 10.1101/2020.11.04.20225805
A1 Kubo, Sousuke
A1 Ohtake, Norihisa
A1 Miyakawa, Kei
A1 Jeremiah, Sundararaj Stanleyraj
A1 Yamaoka, Yutaro
A1 Murohashi, Kota
A1 Hagiwara, Eri
A1 Mihara, Takahiro
A1 Goto, Atsushi
A1 Yamazaki, Etsuko
A1 Ogura, Takashi
A1 Kaneko, Takeshi
A1 Yamanaka, Takeharu
A1 Ryo, Akihide
YR 2020
UL http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225805.abstract
AB Objective Serological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against two of the most immunologically relevant SARS-CoV-2 antigens, nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples.Methods We designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP (ΔN-NP) or receptor-binding domain (RBD) antigen) on the advanced chemiluminescence enzyme immunoassay system TOSOH AIA-CL. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera. Subsequently, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors.Results All of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63-100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63-100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested.Conclusion Our newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.Competing Interest StatementN.O. is a current employee of Tosoh Corporation. Y.Y. is a current employee of Kanto Chemical Co., Inc. The authors declare that there is no conflict of interest directly relevant to the content of this article.Funding StatementThis work was in part supported by Rapid Research and Development Projects on COVID-19 of Japan Agency for Medical Research and Development (AMED) (JP19fk0108110, JP20he0522001), Health and Labor Sciences Research Grants (19HA1003) and Life Innovation Platform Yokohama from Economic Affairs Bureau City of Yokohama to AR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed according to protocols approved by Yokohama City University Hospital and Kanagawa Cardiovascular and Respiratory Center institutional review board (B160800009, B200600115)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are available upon request as they contain potentially identifying or sensitive patient information. This policy follows the restrictions imposed by Yokohama City University Hospital and Kanagawa Cardiovascular and Respiratory Center institutional review board that approved the study. Electronic health record data cannot be shared publicly because they consists of personal information from which it is difficult to guarantee de-identification. As a result, there is a possibility of deductive disclosure of participants and therefore full data access through a public repository is not permitted by the institutions that provided us the data. The data and associated documentation from each collaborating institution can only be made available under a new data sharing agreement with which includes: 1) commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate measures, and 3) a commitment to destroy or return the data after analyses are complete. Requests can be made directly at aryo @yokohama-cu.ac.jp